Since the outbreak of the COVID-19 pandemic, the market for Celecoxib and Naproxen+PPI has continued to grow.
According to IQVIA, the Celecoxib market grew more than 9% in the first quarter to reach 20 billion won, and the Naproxen+PPI combination drug market also expanded by 9% to over 7 billion won.
In the Celecoxib market, Celebrex (Viatris) sales stagnated at 9.3 billion won, while Cybrex (HUTECS Korea), Celexstar (Eden Pharma), and Celcobrex (Arlico Pharm) exceeded 600 million won.
Coxbito (Chong Kun Dang Pharmaceutical) recorded a slightly sluggish performance YoY, but maintained at 500 million won mark, followed by Celeb (Celltrion Pharm), Cele V (HANLIM PHARM), and Klicox (Samjin Pharmaceutical) with 400 million won mark.
Moreover, Beacoxib (Daewoong Bio), Coxib (Hanmi Pharmaceutical), and Celcok (Whanin Pharmaceutical) posted more than 100 million won per month on average.
In the Naproxen+PPI market, Naxozole (Hanmi Pharmaceutical) and Vimovo (AstraZeneca) surpassed 3 billion won.
Naxozole took the lead with sales close to 3.1 billion won, and Vimovo ranked second with sales close to 3 billion won.
Followed by two leaders, Naxen S (Chong Kun Dang Pharmaceutical) entered the 700 million won mark, while Nafmed (SK Chemicals), Esoroxen (Korean Drug Co.), and Naprazole (Alvogen Korea) made 100 million won mark.
